ACHV · CIK 0000949858 · operating
# Achieve Life Sciences, Inc. (ACHV)
Achieve Life Sciences is a late-stage pharmaceutical company developing cytisinicline, a plant-based alkaloid derived from the Cytisus laborinum plant, for smoking cessation treatment. Cytisinicline operates by binding to nicotine receptors in the brain, reducing the severity of nicotine withdrawal symptoms and cravings associated with smoking cessation. The company is advancing cytisinicline toward regulatory approval and commercialization across North America and the United Kingdom through a licensing and supply agreement with Sopharma AD, a Bulgarian pharmaceutical manufacturer, and a research collaboration with the University of Bristol.
The company's primary focus is the development and commercialization of cytisinicline as a therapeutic option for nicotine dependence. Revenue generation is currently limited as the company remains in late-stage development. Achieve Life Sciences operates with a lean infrastructure, maintaining 25 full-time employees and is headquartered in Bothell, Washington.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2024 | $-1.24 | $-1.24 | +17.3% | |
| 2023 | $-1.50 | $-1.50 | +62.5% | |
| 2022 | $-4.00 | $-4.00 | — | |
| 2021 | — | — | — | |
| 2020 | — | — | — | |
| 2019 | — | — | — | |
| 2018 | — | — | — | |
| 2017 | — | — | — | |
| 2016 | — | — | — | |
| 2015 | — | — | — | |
| 2014 | — | — | — | |
| 2013 | — | — | — | |
| 2012 | $-0.98 | $-0.98 | — | |
| 2011 | — | — | — |
| Report Date | Filed | Accession Number | |
|---|---|---|---|
| 2024-12-31 | 2025-03-11 | 0000950170-25-036831 | SEC ↗ |
| 2023-12-31 | 2024-03-28 | 0000950170-24-038049 | SEC ↗ |
| 2022-12-31 | 2023-03-16 | 0001564590-23-003800 | SEC ↗ |
| 2021-12-31 | 2022-03-10 | 0001564590-22-009485 | SEC ↗ |
| 2020-12-31 | 2021-03-11 | 0001564590-21-012523 | SEC ↗ |
| 2019-12-31 | 2020-03-13 | 0001564590-20-010642 | SEC ↗ |
| 2018-12-31 | 2019-03-14 | 0001564590-19-007838 | SEC ↗ |
| 2017-12-31 | 2018-03-01 | 0001564590-18-004159 | SEC ↗ |
| 2016-12-31 | 2017-02-23 | 0001564590-17-002109 | SEC ↗ |
| 2015-12-31 | 2016-03-09 | 0001564590-16-014302 | SEC ↗ |
| 2014-12-31 | 2015-03-26 | 0001564590-15-002010 | SEC ↗ |
| 2013-12-31 | 2014-03-11 | 0001193125-14-093757 | SEC ↗ |
| 2012-12-31 | 2013-03-07 | 0001193125-13-096041 | SEC ↗ |
| 2011-12-31 | 2012-03-08 | 0001193125-12-103884 | SEC ↗ |
| 2010-12-31 | 2011-03-10 | 0000950123-11-024138 | SEC ↗ |
| 2009-12-31 | 2010-03-08 | 0000950123-10-022087 | SEC ↗ |
| 2008-12-31 | 2009-03-11 | 0001362310-09-003566 | SEC ↗ |